SGLT2 Transdermal Patch With Acrylic Adhesive for Sustained Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral administration of SGLT2 inhibitors for Type 2 diabetes is invasive and can cause liver metabolism-related side effects, necessitating a minimally invasive and effective alternative delivery method.
Innovation Solution
A transdermal patch comprising a mixture of SGLT2 inhibitors and an acrylic adhesive, designed with specific adhesion properties and permeation profiles to deliver the drug through the skin over an extended period.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral administration of SGLT2 inhibitors is used, then the drug can be delivered systemically, but liver metabolism-related side effects occur
Solution Approach 1:
The patent uses the skin and transdermal patch as an intermediary delivery system to transport SGLT2 inhibitors directly into the bloodstream, bypassing the liver's first-pass metabolism. This mediator approach eliminates liver metabolism-related side effects while maintaining therapeutic efficacy through sustained drug release.
2Object-affected harmful factors
If transdermal delivery is used, then liver metabolism is bypassed, but sustained delivery over extended periods is challenging
Solution Approach 1:
The patent employs drug-in-adhesive formulations with carefully controlled drug loading concentrations and adhesive properties to achieve sustained transdermal delivery. By adjusting formulation parameters such as drug concentration, adhesive composition, and patch design, the system maintains stable drug release rates over extended periods (7 days or longer), bypassing liver metabolism while ensuring prolonged therapeutic action.
3Ease of operation
If transdermal patch with drug-in-adhesive is used, then minimally invasive delivery is achieved, but adhesion and permeation properties must be precisely controlled
Solution Approach 1:
The patent utilizes composite drug-in-adhesive formulations combining SGLT2 inhibitors with specialized acrylic adhesives. This composite material approach integrates both adhesion function and drug delivery capability into a single layer, ensuring precise control over both skin attachment and drug permeation properties while maintaining ease of application as a minimally invasive patch.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdermal patch provides sustained delivery of SGLT2 inhibitors for at least 7 days with reduced liver metabolism, minimizing side effects and maintaining therapeutic efficacy.
Implementation Method 1
designed with specific adhesion properties and permeation profiles to deliver the drug through the skin over an extended period
Data Source
AI summary
Disclosed herein are compositions and methods for transdermal formulations of antidiabetic agents. An example transdermal formulation contains a SGLT2 inhibitor, and is used for the treatment of Type 2 diabetes.